UGT1A1*6基因分型在接受伊立替康治疗的日本癌症患者中的必要性。 - Suppr

Suppr

超能文献

Indispensability of UGT1A1*6 genotyping in Japanese cancer patients treated with irinotecan.

作者信息

Takano Masashi, Kato Masafumi, Yoshikawa Tomoyuki, Goto Tomoko, Furuya Kenichi, Kikuchi Yoshihiro

出版信息

Int J Clin Oncol. 2010 Apr;15(2):224-5. doi: 10.1007/s10147-010-0024-2. Epub 2010 Feb 24.

DOI:10.1007/s10147-010-0024-2

PMID:20179984

Abstract

摘要

相似文献

Indispensability of UGT1A1*6 genotyping in Japanese cancer patients treated with irinotecan.UGT1A1*6基因分型在接受伊立替康治疗的日本癌症患者中的必要性。

Int J Clin Oncol. 2010 Apr;15(2):224-5. doi: 10.1007/s10147-010-0024-2. Epub 2010 Feb 24.

Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients.UDP-葡糖醛酸基转移酶1A1*6对日本癌症患者伊立替康毒性的重要性。

Cancer Lett. 2008 Mar 18;261(2):165-71. doi: 10.1016/j.canlet.2007.11.009. Epub 2007 Dec 20.

The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians: a meta-analysis.UGT1A1*6 和 UGT1A1*28 与亚洲人伊立替康诱导中性粒细胞减少的关联：一项荟萃分析。

Biomarkers. 2014 Feb;19(1):56-62. doi: 10.3109/1354750X.2013.867534. Epub 2013 Dec 6.

UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis.UGT1A1*6基因多态性与伊立替康所致中性粒细胞减少症的相关性：一项系统评价和荟萃分析

Cancer Chemother Pharmacol. 2017 Jul;80(1):135-149. doi: 10.1007/s00280-017-3344-3. Epub 2017 Jun 5.

UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients.UGT1A1*6基因多态性最能预测日本癌症患者中由伊立替康引起的严重中性粒细胞减少症。

Int J Clin Oncol. 2009 Apr;14(2):136-42. doi: 10.1007/s10147-008-0821-z. Epub 2009 Apr 24.

Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapy.对接受伊立替康化疗的日本患者进行UGT1A1*28和*6基因检测。

Ann Oncol. 2008 Dec;19(12):2089-90. doi: 10.1093/annonc/mdn645. Epub 2008 Oct 26.

UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients.UGT1A1 6/28 多态性可预测中国结直肠癌患者伊立替康引起的严重中性粒细胞减少而非腹泻。

Med Oncol. 2013;30(3):604. doi: 10.1007/s12032-013-0604-x. Epub 2013 May 18.

UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians.UGT1A1*6 多态性与伊立替康诱导的毒性相关：亚洲人群的系统评价和荟萃分析。

Cancer Chemother Pharmacol. 2014 Mar;73(3):551-60. doi: 10.1007/s00280-014-2382-3. Epub 2014 Jan 22.

Insights, challenges, and future directions in irinogenetics.伊立替康遗传学的见解、挑战及未来方向

Ther Drug Monit. 2007 Jun;29(3):265-70. doi: 10.1097/FTD.0b013e318068623b.

UGT1A1 polymorphism predicts irinotecan toxicity: evolving proof.UGT1A1基因多态性可预测伊立替康毒性：不断演变的证据。

AAPS PharmSci. 2001;3(3):3. doi: 10.1208/ps0303_commentary2.

引用本文的文献

Geographic difference in advanced gastric cancer prevalence and chemotherapy treatment results: could it really be an independent prognostic factor?

Gastric Cancer. 2012 Jul;15(3):232-4. doi: 10.1007/s10120-011-0131-4.

本文引用的文献

Int J Clin Oncol. 2009 Apr;14(2):136-42. doi: 10.1007/s10147-008-0821-z. Epub 2009 Apr 24.

Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study.尿苷二磷酸葡萄糖醛酸基转移酶1A1*6对妇科癌症中伊立替康和顺铂联合化疗毒性的临床意义：一项前瞻性多机构研究。

Oncology. 2009;76(5):315-21. doi: 10.1159/000209335. Epub 2009 Mar 20.

Re: UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.关于：尿苷二磷酸葡萄糖醛酸转移酶1A1*28基因型与伊立替康诱导的中性粒细胞减少症：剂量至关重要。

J Natl Cancer Inst. 2008 Feb 6;100(3):224-5; author reply 225. doi: 10.1093/jnci/djm302. Epub 2008 Jan 29.

UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.UGT1A1*28基因分型与伊立替康诱导的中性粒细胞减少：剂量至关重要。

J Natl Cancer Inst. 2007 Sep 5;99(17):1290-5. doi: 10.1093/jnci/djm115. Epub 2007 Aug 28.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验